Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/24/26
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/24/26
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 02/24/26
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewsWire • 02/23/26
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual MeetingGlobeNewsWire • 02/19/26
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to DeclineZacks Investment Research • 02/17/26
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 02/10/26
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?Zacks Investment Research • 01/29/26
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600PRNewsWire • 01/27/26
Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/26
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGNGlobeNewsWire • 12/03/25
Apellis Pharmaceuticals, Inc. (APLS) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
Apellis Pharmaceuticals, Inc. (APLS) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/02/25
Apellis Pharmaceuticals, Inc. (APLS) Presents at Stifel 2025 Healthcare Conference TranscriptSeeking Alpha • 11/12/25
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 YearsGlobeNewsWire • 11/12/25